Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Conference Abstracts
, 2015, 'beta III-Tubulin Regulates Sensitivity to Nab-Paclitaxel (Abraxane (R)) in Pancreatic Cancer', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, Vol. 44, pp. 1414 - 1415, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000363324000260&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2015, 'beta IVb-Tubulin is a Novel Therapeutic Target for the Treatment of Pancreatic Cancer', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, Vol. 44, pp. 1414 - 1414, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000363324000259&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2015, 'RITUXIMAB TO TREAT GEMCITABINE INDUCED HEMOLYTIC URAEMIC SYNDROME IN THREE PATIENTS WITH PANCREATIC ADNENOCARCINOMA', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 11, pp. 63 - 63, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357957300056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2015, 'Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized, multidisciplinary, multinational phase III trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps4140
, 2015, 'Antiangiogenic agents (AAs) in metastatic oesophago-gastric cancer (mOGC): A systematic review and meta-analysis', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.e15111
, 2015, 'Reduction in primary pancreatic and metastatic tumor burden in the phase III MPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.e15299
, 2015, 'A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 33, pp. 4115 - 4115, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.4115
, 2015, 'INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)—Final overall and subgroup results.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 33, pp. 4003 - 4003, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.4003
, 2015, 'nab -paclitaxel ( nab -P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 33, pp. tps4153 - tps4153, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps4153
, 2015, 'Effective Delivery of siRNA into Cancer Cells and Tumors Using Well-Defined Biodegradable Cationic Star Polymers (vol 10, pg 2435, 2013)', in MOLECULAR PHARMACEUTICS, AMER CHEMICAL SOC, Vol. 12, pp. 1004 - 1004, http://dx.doi.org/10.1021/acs.molpharmaceut.5b00092
, 2015, 'A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 33, pp. 387 - 387, http://dx.doi.org/10.1200/jco.2015.33.3_suppl.387
, 2015, 'P1310 : Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1) – a randomized, multidisciplinary, multinational phase III trial', in Journal of Hepatology, Elsevier, Vol. 62, pp. s845, http://dx.doi.org/10.1016/s0168-8278(15)31489-6
, 2015, 'Synergistic effects of concurrent inhibition of EGFR and STAT3 in soft tissue sarcoma cell lines', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, AUSTRIA, Vienna, Vol. 51, pp. S704 - S705, presented at European Cancer Congress, AUSTRIA, Vienna, http://dx.doi.org/10.1016/S0959-8049(16)31921-9
, 2014, 'APACT: a Phase III Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) vs Gem Alone as Adjuvant Therapy for Patients (pts) with Resected Pancreatic Cancer (PC)', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, Vol. 43, pp. 1416 - 1416, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344362600355&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'WORKING WITH PATIENTS FROM CULTURALLY AND LINGUISTICALLY DIVERSE BACKGROUNDS: PERSPECTIVES OF ONCOLOGY HEALTH PROFESSIONALS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 9, pp. 130 - 130, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800222&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 31, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419603085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2012, 'CURRENT CARE AND NEEDS OF ADULT CANCER SURVIVORS - A CROSS-SECTIONAL SURVEY', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 8, pp. 356 - 357, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310544400419&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2012, 'Disparities in quality-of-life outcomes in immigrant cancer patients.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 30, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802650&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2011, 'Cancer in a country not your own: Illness perceptions and distress in immigrant versus native-born cancer patients', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, pp. 81 - 81
, 2009, 'Oncology consultations with patients from culturally and linguistically diverse (CALD) backgrounds: the interpreter perspective', in Psycho-oncology, John Wiley & Sons, New York, pp. 46 - 46
, 2009, 'Oncology consultations with patients from culturally and linguistically diverse backgrounds – the interpreters’ perceptions of roles, challenges, and support needs', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, pp. 207 - 207
, 2009, 'Unmet needs in Chinese, Greek, and Arabic-speaking cancer patients in New South Wales', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, pp. 221 - 221
, 2009, 'Unmet needs in Chinese, Greek, Arabic, and English-speaking cancer patients in New South Wales', in Psycho-oncology, John Wiley & Sons, New York, pp. 117 - 117
, 2008, 'Barriers to research with cancer patients from culturally and linguistically diverse (CALD) communities in Australia', in Psycho-oncology, John Wiley & Sons, New York, pp. S280 - S280
, 2008, 'Conducting research with culturally and linguistically diversre cancer patients: methodological issues', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, pp. 40 - 40
, 2008, 'Unmet needs in Chinese, Greek and Arabic speaking cancer patients in Australia', in Psycho-oncology, John Wiley & Sons, New York, pp. S7 - S7
, 2007, 'Barriers to research with cancer patients from culturally and linguistically diverse (CALD) communities in Australia', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, pp. A95 - A96
, 2007, 'Low psychological service utilisation in cancer – does it mean CALD patients cope better', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, pp. A96 - A96
, 2007, 'Psychological morbidity or unmet needs of cancer patients from culturally and linguistically diverse (CALD) backgrounds', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, pp. A67 - A67
Preprints
, 2022, Value of Central Review of RECIST v1.1 Outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer, http://dx.doi.org/10.21203/rs.3.rs-1960530/v1
, A phase 2, open-label, single-arm monotherapy trial of Sulfasalazine in patients with PancrEatic AdenocaRcinoma: Statistical analysis plan for the SPEAR study, http://dx.doi.org/10.64898/2025.12.04.25341652
, Bringing the pancreas patient back to the bench: Ex vivo culture of intact human patient derived pancreatic tumour tissue, http://dx.doi.org/10.1101/2020.07.30.223925
, Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to SLC7A11 inhibition, http://dx.doi.org/10.1101/2020.07.12.199638
, Computed Tomography Radiomics Signatures: Sensitive biomarkers for clinical decision support in pancreatic cancer- a pilot study, http://dx.doi.org/10.1101/2021.12.03.21267217
, Peripheral Neuropathy in Cancer Patients- Multifactorial Contributors to Dose Limiting and Chronic Toxicity, http://dx.doi.org/10.1101/2024.07.24.24310956
, Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study, http://dx.doi.org/10.21203/rs.3.rs-1190781/v1
, βIII-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer, http://dx.doi.org/10.1101/2022.09.29.510034
Other
, 2023, Data from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.c.6512931.v1
, 2023, Data from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.c.6512931
, 2023, Figure S1 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428180.v1
, 2023, Figure S1 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428180
, 2023, Figure S2 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428177.v1
, 2023, Figure S2 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428177
, 2023, Figure S3 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428168.v1
, 2023, Figure S3 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428168
, 2023, Figure S4 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428165.v1
, 2023, Figure S4 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428165
, 2023, Supplementary Table 1 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428162
, 2023, Supplementary Table 1 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428162.v1
, 2023, Supplementary Table 2 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428159.v1